

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

Clinical summary

The purpose of the study is to determine safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab [an anti-Programmed cell Death-1(anti-PD1) antibody] in patients with advanced cancers.

Conditions

This trial is treating patients with advanced cancers (excluding blood cancer)

Trial Acronym

IDO COMBO

Trial Identifiers

NCT02658890

BMS CA017-003, 2015-004914-79

Cancer

Anus, Astrocytoma, Basal cell carcinoma, Bile duct, Bladder, Bone, Brain, Brain stem, Breast, Cervix, Chondrosarcoma, Colon, Colorectum, Cutaneous Squamous Cell Carcinoma (CSCC), Endometrium, Ependymomas, Epithelial, Ewing's Sarcoma, Fallopian tube, Gallbladder, Gastrointestinal stromal tumors (GISTs), Gastro-oesophageal junction , Germ cell and sex cord stromal cell, Glioma, Kidney, Leiomyosarcoma, Liposarcoma, Liver, Medullablastoma, Melanoma (Ocular), Melanoma (Skin), Meningioma, Merkel cell, Mesothelioma, Neuroblastoma, Neuroendocrine tumours, Non-Small Cell Lung Cancer, Nose (nasopharynx), Oesophagus, Oral cavity, Oropharynx, Osteosarcoma, Ovary, Pancreas, Penis, Peritoneal, Prostate, Rectum, Renal cell carcinoma, Rhabdomyosarcoma, Salivary glands, Sarcoma, Small Cell Lung Cancer, Soft Tissue Sarcoma, Spinal Cord, Stomach, Synovial Sarcoma, Testis, Throat (hypopharynx), Thyroid, Urinary tract, Urothelial, Uterus, Vagina, Voice box (larynx), Vulva

Age: 18+

Phase: I/II

